Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents
Broschiertes Buch

Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents

Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 & 28, 1988

Herausgegeben: Morganroth, J.; Moore, E. Neil
Versandkostenfrei!
Versandfertig in 1-2 Wochen
153,99 €
inkl. MwSt.
Weitere Ausgaben:
PAYBACK Punkte
77 °P sammeln!
The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s)...